비경구 항생제 시장 - 규모, 점유율, 성장률, 산업 분석 : 유형별, 용도별, 지역별 인사이트 및 예측(2026-2034년)

Growth Factors of parenteral antibiotics Market

The global parenteral antibiotics market has witnessed significant growth due to the increasing prevalence of severe infections and the critical role of injectable antibiotics in hospital and critical care settings. The market was valued at USD 25.09 billion in 2025 and is projected to grow to USD 26.04 billion in 2026, reaching USD 37.15 billion by 2034, exhibiting a CAGR of 4.50%. North America dominated the market in 2025 with a market share of 45.51%, driven by advanced healthcare infrastructure, high hospitalization rates, and strong adoption of intravenous therapies.

Parenteral antibiotics, administered through intramuscular (IM) or intravenous (IV) routes, are essential in managing critical infections such as sepsis, hospital-acquired infections (HAIs), pneumonia, and complicated urinary tract infections. Their fast-acting nature, high bioavailability, and ability to manage drug-resistant infections make them highly preferred in clinical settings.

Market Dynamics

Market Drivers

The growth of the parenteral antibiotics market is largely propelled by increasing hospitalization due to severe infections and the rise of chronic diseases requiring surgical interventions. Outpatient Parenteral Antibiotic Therapy (OPAT) is becoming an effective alternative to hospital-based IV therapy, reducing hospital stays while maintaining efficacy. Additionally, immunocompromised populations, including patients with HIV/AIDS, cancer, and autoimmune diseases, contribute to higher demand for parenteral antibiotics. HAIs, which affect one in ten patients globally, further boost market growth due to the need for potent antibiotic treatments.

Market Restraints

Barriers to access in emerging countries restrict market expansion. Challenges include weak healthcare infrastructure, poverty, high out-of-pocket spending, and dependence on selective countries for active pharmaceutical ingredients (APIs). These factors limit the availability and affordability of injectable antibiotics, particularly in low- and middle-income countries (LMICs).

Market Opportunities

The cost-effectiveness of OPAT programs offers significant growth potential. By allowing patients to receive IV antibiotics in outpatient or home settings, healthcare systems benefit from reduced hospitalization costs, optimized resource allocation, and improved patient satisfaction. This shift toward home-based therapy is expected to create substantial opportunities for market players.

Market Challenges

The low profitability of antibiotic R&D and complex regulatory processes pose significant challenges. Short treatment durations, restrictive reimbursement policies, and prolonged global approval timelines discourage heavy investment in new parenteral antibiotic development. These challenges make sustained innovation and pipeline expansion difficult for companies.

Market Trends

A key trend is the rising adoption of combination therapies to combat multidrug-resistant pathogens. Combining drugs broadens the antimicrobial spectrum, enhances treatment efficacy, and reduces resistance emergence. For example, the combination of MBL inhibitor indole-2-carboxylate 58 (InC58), B-lactam antibiotic meropenem, and SBL inhibitor avibactam (AVI) has shown promising results against resistant Gram-negative bacteria.

Segmentation Analysis

By Drug Class: Penicillin dominated in 2024 and continues to hold the largest share, driven by its widespread use for meningitis, throat infections, syphilis, and other indications. Cephalosporins also maintain a strong presence, supported by multi-generational formulations targeting diverse bacterial infections. Macrolides, fluoroquinolones, tetracyclines, and sulfonamides are projected to grow steadily due to increased adoption and availability of generics.

By Application: Respiratory infections, including pneumonia and tuberculosis, represent the largest segment in 2024, driven by increasing incidence and severity of bacterial infections. Urinary tract infections (UTIs) hold the second-largest position due to rising prevalence, particularly in women, and ongoing product launches.

By Distribution Channel: Hospital pharmacies remain the largest distribution segment due to immediate access to high-potency injectable antibiotics for critical patients. Online pharmacies are the fastest-growing channel, accelerated by home delivery trends and the COVID-19 pandemic, which enhanced consumer adoption of e-commerce healthcare solutions.

Regional Outlook

North America led the market with USD 11.42 billion in 2025, supported by an aging population, higher prevalence of bacterial infections, and advanced healthcare infrastructure. The U.S. dominates regional sales, driven by strategic collaborations and rising antimicrobial resistance. Europe ranks second, with high antibiotic consumption and collaborations boosting growth. Asia Pacific is the fastest-growing market, fueled by increasing approvals, high antibiotic demand, and rapid commercialization of innovative parenteral antibiotics. Latin America and the Middle East & Africa are expected to witness moderate but steady growth due to rising awareness and government-led infection control initiatives.

Competitive Landscape

The parenteral antibiotics market is fragmented, with key players such as Pfizer Inc., GSK plc., Bayer AG, Bristol-Myers Squibb, Merck & Co., AbbVie Inc., and Cipla leading the market. These companies focus on strategic initiatives including new product launches, generic introductions, partnerships, and collaborations to expand their presence in hospitals, outpatient settings, and emerging markets.

Conclusion

The global parenteral antibiotics market is poised for robust growth from USD 25.09 billion in 2025 to USD 37.15 billion by 2034. Rising incidences of severe infections, increasing hospitalizations, and adoption of OPAT programs are driving demand. While regulatory challenges and low R&D profitability remain concerns, strategic partnerships, generic drug launches, combination therapies, and rapid commercialization in emerging markets present significant growth opportunities. Companies that focus on innovation, antimicrobial resistance solutions, and efficient distribution channels are well-positioned to strengthen their market share over the forecast period.

Segmentation By Drug Class

• Penicillin
• Cephalosporin
• Aminoglycosides
• Tetracycline
• Macrolides
• Fluoroquinolones
• Sulfonamides
• Others

By Application

• Skin Infections
• Respiratory Infections
• Urinary Tract Infections
• Septicemia
• Gastrointestinal Infections
• Others

By Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

By Region

• North America (By Drug Class, Application, Distribution Channel, and Country/Sub-region)
  • U.S.
  • Canada
• Europe (By Drug Class, Application, Distribution Channel, and Country/Sub-region)
  • U.K.
  • Germany
  • France
  • Italy
  • Spain
  • Scandinavia
  • Rest of Europe
• Asia Pacific (By Drug Class, Application, Distribution Channel, and Country/Sub-region)
  • Japan
  • China
  • India
  • Australia
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America (By Drug Class, Application, Distribution Channel, and Country/Sub-region)
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa (By Drug Class, Application, Distribution Channel, and Country/Sub-region)
  • GCC
  • South Africa
  • Rest of the Middle East & Africa

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology
• 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Market Trends

4. Key Insights

• 4.1. Prevalence of Key Diseases, By Key Countries/Regions, 2025
• 4.2. Reimbursement Scenario, By Key Countries/Regions
• 4.3. Pipeline Analysis, By Key Players
• 4.4. Overview: Technological Advancements in Parenteral Antibiotics Delivery
• 4.5. New Product Launches, By Key Players
• 4.6. Key Industry Developments Such as Mergers, Acquisitions, and Partnerships

5. Global Parenteral Antibiotics Market Analysis, Insights and Forecast, 2021-2034

• 5.1. Market Analysis, Insights and Forecast - By Drug Class
  • 5.1.1. Penicillin
  • 5.1.2. Cephalosporin
  • 5.1.3. Aminoglycosides
  • 5.1.4. Tetracycline
  • 5.1.5. Macrolides
  • 5.1.6. Fluoroquinolones
  • 5.1.7. Sulfonamides
  • 5.1.8. Others
• 5.2. Market Analysis, Insights and Forecast - By Application
  • 5.2.1. Skin Infections
  • 5.2.2. Respiratory Infections
  • 5.2.3. Urinary Tract Infections
  • 5.2.4. Septicemia
  • 5.2.5. Gastrointestinal Infections
  • 5.2.6. Others
• 5.3. Market Analysis, Insights and Forecast - By Distribution Channel
  • 5.3.1. Hospital Pharmacy
  • 5.3.2. Retail Pharmacy
  • 5.3.3. Online Pharmacy
• 5.4. Market Analysis, Insights and Forecast - By Region
  • 5.4.1. North America
  • 5.4.2. Europe
  • 5.4.3. Asia Pacific
  • 5.4.4. Latin America
  • 5.4.5. Middle East & Africa

6. North America Parenteral Antibiotics Market Analysis, Insights and Forecast, 2021-2034

• 6.1. Market Analysis, Insights and Forecast - By Drug Class
  • 6.1.1. Penicillin
  • 6.1.2. Cephalosporin
  • 6.1.3. Aminoglycosides
  • 6.1.4. Tetracycline
  • 6.1.5. Macrolides
  • 6.1.6. Fluoroquinolones
  • 6.1.7. Sulfonamides
  • 6.1.8. Others
• 6.2. Market Analysis, Insights and Forecast - By Application
  • 6.2.1. Skin Infections
  • 6.2.2. Respiratory Infections
  • 6.2.3. Urinary Tract Infections
  • 6.2.4. Septicemia
  • 6.2.5. Gastrointestinal Infections
  • 6.2.6. Others
• 6.3. Market Analysis, Insights and Forecast - By Distribution Channel
  • 6.3.1. Hospital Pharmacy
  • 6.3.2. Retail Pharmacy
  • 6.3.3. Online Pharmacy
• 6.4. Market Analysis, Insights and Forecast - By Country
  • 6.4.1. U.S.
  • 6.4.2. Canada

7. Europe Parenteral Antibiotics Market Analysis, Insights and Forecast, 2021-2034

• 7.1. Market Analysis, Insights and Forecast - By Drug Class
  • 7.1.1. Penicillin
  • 7.1.2. Cephalosporin
  • 7.1.3. Aminoglycosides
  • 7.1.4. Tetracycline
  • 7.1.5. Macrolides
  • 7.1.6. Fluoroquinolones
  • 7.1.7. Sulfonamides
  • 7.1.8. Others
• 7.2. Market Analysis, Insights and Forecast - By Application
  • 7.2.1. Skin Infections
  • 7.2.2. Respiratory Infections
  • 7.2.3. Urinary Tract Infections
  • 7.2.4. Septicemia
  • 7.2.5. Gastrointestinal Infections
  • 7.2.6. Others
• 7.3. Market Analysis, Insights and Forecast - By Distribution Channel
  • 7.3.1. Hospital Pharmacy
  • 7.3.2. Retail Pharmacy
  • 7.3.3. Online Pharmacy
• 7.4. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 7.4.1. U.K.
  • 7.4.2. Germany
  • 7.4.3. France
  • 7.4.4. Spain
  • 7.4.5. Italy
  • 7.4.6. Scandinavia
  • 7.4.7. Rest of Europe

8. Asia Pacific Parenteral Antibiotics Market Analysis, Insights and Forecast, 2021-2034

• 8.1. Market Analysis, Insights and Forecast - By Drug Class
  • 8.1.1. Penicillin
  • 8.1.2. Cephalosporin
  • 8.1.3. Aminoglycosides
  • 8.1.4. Tetracycline
  • 8.1.5. Macrolides
  • 8.1.6. Fluoroquinolones
  • 8.1.7. Sulfonamides
  • 8.1.8. Others
• 8.2. Market Analysis, Insights and Forecast - By Application
  • 8.2.1. Skin Infections
  • 8.2.2. Respiratory Infections
  • 8.2.3. Urinary Tract Infections
  • 8.2.4. Septicemia
  • 8.2.5. Gastrointestinal Infections
  • 8.2.6. Others
• 8.3. Market Analysis, Insights and Forecast - By Distribution Channel
  • 8.3.1. Hospital Pharmacy
  • 8.3.2. Retail Pharmacy
  • 8.3.3. Online Pharmacy
• 8.4. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 8.4.1. Japan
  • 8.4.2. China
  • 8.4.3. India
  • 8.4.4. Australia
  • 8.4.5. Southeast Asia
  • 8.4.6. Rest of Asia Pacific

9. Latin America Parenteral Antibiotics Market Analysis, Insights and Forecast, 2021-2034

• 9.1. Market Analysis, Insights and Forecast - By Drug Class
  • 9.1.1. Penicillin
  • 9.1.2. Cephalosporin
  • 9.1.3. Aminoglycosides
  • 9.1.4. Tetracycline
  • 9.1.5. Macrolides
  • 9.1.6. Fluoroquinolones
  • 9.1.7. Sulfonamides
  • 9.1.8. Others
• 9.2. Market Analysis, Insights and Forecast - By Application
  • 9.2.1. Skin Infections
  • 9.2.2. Respiratory Infections
  • 9.2.3. Urinary Tract Infections
  • 9.2.4. Septicemia
  • 9.2.5. Gastrointestinal Infections
  • 9.2.6. Others
• 9.3. Market Analysis, Insights and Forecast - By Distribution Channel
  • 9.3.1. Hospital Pharmacy
  • 9.3.2. Retail Pharmacy
  • 9.3.3. Online Pharmacy
• 9.4. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 9.4.1. Brazil
  • 9.4.2. Mexico
  • 9.4.3. Rest of Latin America

10. Middle East & Africa Parenteral Antibiotics Market Analysis, Insights and Forecast, 2021-2034

• 10.1. Market Analysis, Insights and Forecast - By Drug Class
  • 10.1.1. Penicillin
  • 10.1.2. Cephalosporin
  • 10.1.3. Aminoglycosides
  • 10.1.4. Tetracycline
  • 10.1.5. Macrolides
  • 10.1.6. Fluoroquinolones
  • 10.1.7. Sulfonamides
  • 10.1.8. Others
• 10.2. Market Analysis, Insights and Forecast - By Application
  • 10.2.1. Skin Infections
  • 10.2.2. Respiratory Infections
  • 10.2.3. Urinary Tract Infections
  • 10.2.4. Septicemia
  • 10.2.5. Gastrointestinal Infections
  • 10.2.6. Others
• 10.3. Market Analysis, Insights and Forecast - By Distribution Channel
  • 10.3.1. Hospital Pharmacy
  • 10.3.2. Retail Pharmacy
  • 10.3.3. Online Pharmacy
• 10.4. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 10.4.1. GCC
  • 10.4.2. South Africa
  • 10.4.3. Rest of Middle East & Africa

11. Competitive Analysis

• 11.1. Global Market Share Analysis (2025)
• 11.2. Company Profiles
  • 11.2.1. Bristol-Myers Squibb Company
    • 11.2.1.1. Overview
    • 11.2.1.2. Products & services
    • 11.2.1.3. SWOT Analysis
    • 11.2.1.4. Recent Developments
    • 11.2.1.5. Strategies
    • 11.2.1.6. Financials (Based on Availability)
  • 11.2.2. Pfizer Inc.
    • 11.2.2.1. Overview
    • 11.2.2.2. Products & services
    • 11.2.2.3. SWOT Analysis
    • 11.2.2.4. Recent Developments
    • 11.2.2.5. Strategies
    • 11.2.2.6. Financials (Based on Availability)
  • 11.2.3. Sandoz Group AG
    • 11.2.3.1. Overview
    • 11.2.3.2. Products & services
    • 11.2.3.3. SWOT Analysis
    • 11.2.3.4. Recent Developments
    • 11.2.3.5. Strategies
    • 11.2.3.6. Financials (Based on Availability)
  • 11.2.4. GSK plc.
    • 11.2.4.1. Overview
    • 11.2.4.2. Products & services
    • 11.2.4.3. SWOT Analysis
    • 11.2.4.4. Recent Developments
    • 11.2.4.5. Strategies
    • 11.2.4.6. Financials (Based on Availability)
  • 11.2.5. Bayer AG
    • 11.2.5.1. Overview
    • 11.2.5.2. Products & services
    • 11.2.5.3. SWOT Analysis
    • 11.2.5.4. Recent Developments
    • 11.2.5.5. Strategies
    • 11.2.5.6. Financials (Based on Availability)
  • 11.2.6. Merck & Co., Inc.
    • 11.2.6.1. Overview
    • 11.2.6.2. Products & services
    • 11.2.6.3. SWOT Analysis
    • 11.2.6.4. Recent Developments
    • 11.2.6.5. Strategies
    • 11.2.6.6. Financials (Based on Availability)
  • 11.2.7. Cipla
    • 11.2.7.1. Overview
    • 11.2.7.2. Products & services
    • 11.2.7.3. SWOT Analysis
    • 11.2.7.4. Recent Developments
    • 11.2.7.5. Strategies
    • 11.2.7.6. Financials (Based on Availability)
  • 11.2.8. AbbVie Inc.
    • 11.2.8.1. Overview
    • 11.2.8.2. Products & services
    • 11.2.8.3. SWOT Analysis
    • 11.2.8.4. Recent Developments
    • 11.2.8.5. Strategies
    • 11.2.8.6. Financials (Based on Availability)
  • 11.2.9. AdvaCare Pharma
    • 11.2.9.1. Overview
    • 11.2.9.2. Products & services
    • 11.2.9.3. SWOT Analysis
    • 11.2.9.4. Recent Developments
    • 11.2.9.5. Strategies
    • 11.2.9.6. Financials (Based on Availability)